BioMedNewsBreaks — Ocean Biomedical Inc. (NASDAQ: OCEA) Share Price Target Increased in FRC Report, Receives US Patent for Cancer Immunotherapy Treatment

June 28, 2023 at 12:25 PM EDT

Ocean Biomedical (NASDAQ: OCEA), a next-generation biopharma company working to accelerate the development and commercialization of compelling new biopharma discoveries, has been spotlighted in a recent Fundamental Research Corp. (“FRC”) report. The equity analyst report increased FRC’s price target of OCEA stock to $17.63 per share, up from its March 2023 of $16.40. According to the report, the uptick was based on several things, including Ocean Biomedical’s $25 million financing facility announced last month; the company being granted two new U.S. patents and one Brazilian patent for drug and vaccine candidates targeting malaria and cancer treatment; positive results from an independent study demonstrating that OCEA “antibodies can suppress glioblastoma (brain) tumor growth by 60%”; and the company’s plans to move forward with the manufacturing and IND-enabling studies needed to submit applications to the FDA to initiate human clinical trials and its diversified development pipeline. The FRC report also noted that the company has received 25 patents and has an additional 38 patent applications currently pending. “We are pleased to see our cumulative efforts and growing strengths recognized by Fundamental Research Corp.’s analyst coverage, especially the diverse potential of our core cancer, fibrosis, and infectious disease programs,” said Ocean Biomedical cofounder and executive chair Dr. Chirinjeev Kathuria in the press release.

In addition, the company recently announced that a broad U.S. patent has been issued to Dr. Jack A. Elias, MD, one of the OCEA’s scientific cofounders. The patent covers bispecific antibodies targeting chitinase 3-like-1 (“CHi3L1”) and programmed cell death protein 1 (“PD-1”), “a promising new approach that has emerged from prior breakthrough discoveries that CHi3L1 is a ‘master regulator’ of tumor growth in multiple visceral cancers.” According to the announcement, these bispecific antibodies have been shown to synergistically kill tumor cells at levels dramatically exceeding the effectiveness of either the anti-CHi3L1 antibody or the anti-PD-1 antibody alone in multiple cancer types and multiple animal models. The patent has been granted for a range of cancers, including prostate, colon, rectal, ovarian, kidney, breast, glioblastoma, melanoma and lung.

To view the full press release, visit https://ibn.fm/ZVNKU

About Ocean Biomedical Inc.

Ocean Biomedical is a Rhode Island-based biopharma company with an innovative business model that accelerates the development and commercialization of scientifically compelling assets from research universities and medical centers. Ocean Biomedical deploys the funding and expertise to move new therapeutic candidates efficiently from the laboratory to the clinic, to the world. Ocean Biomedical is currently developing five promising discoveries that have the potential to achieve life-changing outcomes in lung cancer, brain cancer and pulmonary fibrosis, as well as the prevention and treatment of malaria. The Ocean Biomedical team is working on solving some of the world’s toughest problems, for the people who need it most. To learn more, visit www.OceanBiomedical.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

About Us

About Cabling Installation & Maintenance

Contact Cabling Installation & Maintenance

Editorial

Advertising and Sponsorship Sales

Subscriptions and Memberships

Feedback/Problems

BioMedNewsBreaks — Ocean Biomedical Inc. (NASDAQ: OCEA) Share Price Target Increased in FRC Report, Receives US Patent for Cancer Immunotherapy Treatment

More News